Bio
Renumathy Dhanasekaran, MD, PhD, is a physician–scientist whose work integrates clinical care, molecular biology, and translational research to advance the understanding and treatment of liver cancer. She completed Gastroenterology fellowship at the Mayo Clinic, Rochester, followed by Transplant Hepatology fellowship and a PhD in Cancer Biology at Stanford University.
At Stanford, her independent research program centered on the immunobiology of HCC. Her laboratory uses spatial and single-cell technologies, patient-derived tissues, and immunocompetent mouse models to identify biomarkers of progression and response, dissect mechanisms of resistance to therapies, and develop molecularly informed therapeutic strategies. Dr. Dhanasekaran's work has been published widely and supported by the NIH/NCI, AASLD, ACG, ALF, Cancer League, Doris Duke Foundation, and others. She is the recipient of multiple honors including the NCI R37 MERIT Award, the Laure Aurelian Research Endowment, and the McCormick Faculty Award.
Clinically, Dr. Dhanasekaran focuses on liver tumors, where she leads a dedicated liver cancer clinic that cares for patients with hepatocellular carcinoma (HCC) and related liver masses. Her clinical program strives to bring cutting-edge diagnostics and emerging therapeutic innovations to the bedside, expand access to curative options such as liver resection and transplantation, and provide timely entry into clinical trials for eligible patients. She is committed to delivering rapid, coordinated, multidisciplinary care while maintaining a deeply compassionate, patient-centered approach.
Dr. Dhanasekaran’s long-term goal is to improve clinical outcomes for patients with liver cancer through personalized care and translational research.
Lab Website https://med.stanford.edu/dhanasekaran-lab.html
